| Patient-reported safety information: a renaissance of pharmacovigilance? L Härmark, J Raine, H Leufkens, IR Edwards, U Moretti, VM Sarinic, ... Drug safety 39, 883-890, 2016 | 66 | 2016 |
| Description of frequencies of reported adverse events following immunization among four different COVID-19 vaccine brands A Kant, J Jansen, L van Balveren, F van Hunsel Drug safety 45 (4), 319-331, 2022 | 43 | 2022 |
| Vitamin B6 in Health Supplements and Neuropathy: Case Series Assessment of Spontaneously Reported Cases F van Hunsel, S van de Koppel, E van Puijenbroek, A Kant Drug safety 41, 859-869, 2018 | 31 | 2018 |
| COVID-19 vaccine reactogenicity–A cohort event monitoring study in the Netherlands using patient reported outcomes L Rolfes, L Härmark, A Kant, L van Balveren, W Hilgersom, F van Hunsel Vaccine 40 (7), 970-976, 2022 | 28 | 2022 |
| Aim and design of pREGnant, the Dutch pregnancy drug register S Vorstenbosch, B Te Winkel, MMHJ van Gelder, A Kant, N Roeleveld, ... Drug Safety 42 (1), 1-12, 2019 | 21 | 2019 |
| Web-based intensive monitoring of adverse events following influenza vaccination in general practice L van Balveren-Slingerland, A Kant, L Härmark Vaccine 33 (19), 2283-2288, 2015 | 21 | 2015 |
| A ‘natural’weight loss product containing sibutramine F van Hunsel, BJ Venhuis, PHJ Keizers, A Kant Drug Testing and Analysis 8 (3-4), 311-314, 2016 | 20 | 2016 |
| The effect of the family physician on improving follow-up after an abnormal Pap smear B Palm, AC Kant, EA Visser, GP Vooijs, W Van Den Bosch, C Van Weel International Journal for Quality in Health Care 9 (4), 277-282, 1997 | 20 | 1997 |
| Preliminary results of a general practice based call system for cervical cancer screening in The Netherlands. BT Palm, AC Kant, WJ van den Bosch, GP Vooijs, C van Weel British journal of general practice 43 (377), 503-506, 1993 | 20 | 1993 |
| General practitioner based screening for cervical cancer: higher participation of women with a higher risk? AC Kant, B Palm, E Wentink, C Van Weel Journal of Medical Screening 4 (1), 35-39, 1997 | 19 | 1997 |
| Measuring the impact of pharmacovigilance activities, challenging but important F van Hunsel, H Gardarsdottir, A de Boer, A Kant British Journal of Clinical Pharmacology 85 (10), 2235, 2019 | 18 | 2019 |
| Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature JW Duijster, T Lieber, S Pacelli, L Van Balveren, LS Ruijs, M Raethke, ... Frontiers in immunology 14, 1078736, 2023 | 15 | 2023 |
| Numbers of spontaneous reports: how to use and interpret? A Kant, F van Hunsel, E van Puijenbroek British journal of clinical pharmacology 88 (3), 1365-1368, 2022 | 13 | 2022 |
| Cellular composition of cervical smears taken by general practitioners AC Kant, B Palm, DJS Dona, AFC Makkus, GP Vooijs, C Weel call system tor, 87, 1995 | 13 | 1995 |
| Implementation of the national cervical cancer screening in general practice and feasibility of a general practice-based call system: The GP's opinion B Palm, AC Kant, W Van Den Bosch, CWB DE BEIJER, MEJ GERRITS, ... Family practice 10 (2), 173-177, 1993 | 13 | 1993 |
| A call system for cervical cancer screening in the Netherlands organised on the basis of general practice I Palm, A Kant, W van den Bosch, P Vooijs, C van Weel The European Journal of General Practice 2 (3), 104-108, 1996 | 11 | 1996 |
| Optimizing safety surveillance for COVID-19 vaccines at the National Pharmacovigilance Centre Lareb: one year of COVID-19 vaccine experience I Oosterhuis, J Scholl, E van Puijenbroek, A Kant, F van Hunsel Drug Safety 46 (1), 65-75, 2023 | 8 | 2023 |
| CYP450 genotype and aggressive behavior on selective serotonin reuptake inhibitors C Ekhart, M Matic, A Kant, E van Puijenbroek, R Schaik Pharmacogenomics 18 (7), 613-620, 2017 | 7 | 2017 |
| Reflections after the Diane affair A Kant, E van Puijenbroek, F van Hunsel Journal of Thrombosis and Haemostasis 12 (9), 1385-1387, 2014 | 7 | 2014 |
| Reported adverse events following influenza vaccination L van Balveren-Slingerland, HC Rümke, AC Kant Nederlands Tijdschrift Voor Geneeskunde 158, A6841-A6841, 2014 | 7 | 2014 |
Florence van HunselLead Safety Innovation, Netherlands Pharmacovigilance Centre LarebAdresse e-mail validée de lareb.nl
